title: Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
abstract: Fidaxomicin (FDX) is a narrow-spectrum antibiotic for the treatment of Clostridium difficile-associated diarrhea. While FDX and rifamycins share the same target (RNA polymerase), FDX exhibits a unique mode of action distinct from that of rifamycins. In comparative microbiological studies with C. difficile, FDX interacted synergistically with rifamycins, demonstrated a lower propensity for the development of resistance to rifamycins, and exhibited no cross-resistance with rifamycins. These results highlight differences in the mechanisms of action of FDX and rifamycins.
authors.affiliation: Optimer Pharmaceuticals, Inc., San Diego, California, USA.
authors.forename: Farah
authors.initials: F
authors.lastname: Babakhani
authors.forename: Jaime
authors.initials: J
authors.lastname: Seddon
authors.forename: Pamela
authors.initials: P
authors.lastname: Sears
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects*; D000077732:Fidaxomicin; D008826:Microbial Sensitivity Tests; D012294:Rifamycins / Q000494:pharmacology*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D012294:Rifamycins; D000077732:Fidaxomicin